The $100,000-Per-Year Pill: How US Health Agencies Choose Pharma Over Patients
By Fran Quigley,
Truthout
| 08. 05. 2016
Untitled Document
Don Reichmuth survived prostate cancer once before, back in 2007, so his physician was concerned when tests recently revealed the cancer had returned. Reichmuth's physician prescribed a drug called enzalutamide, marketed by the Japanese company Astellas Pharma, Inc. under the brand name Xtandi. But when the physician sent the prescription to the pharmacy, the managers of Reichmuth's insurance plan sent back an immediate refusal to approve it.
Reichmuth, a retired teacher who lives in Washington State, was puzzled by the logic. Then he learned the price of the Xtandi prescription: over $9,700 each month.
Reichmuth is just one of millions of Americans who are experiencing prescription drug sticker shock. There are the extreme high-profile examples, like the former hedge fund manager Martin Shkreli hiking the price of a critical toxoplasmosis drug by 5,000 percent overnight, or a new hepatitis C medicine costing over $1,000 a pill. But the issue extends beyond the headlines. Pharmaceutical corporations consistently set most of their prices hundreds of times higher than their manufacturing costs, then relentlessly raise those prices at rates far...
Related Articles
By Ali Breland, The Atlantic | 08.20.2024
“Joining us now is Steve Sailer, who I find to be incredibly interesting, and one of the most talented noticers,” Charlie Kirk said on his internet show in October. Kirk, the 30-year-old founder of Turning Point USA, a right-wing...
By Megan Agnew, The Times | 09.15.2024
Faith Hartley always wanted two girls — a blonde and a redhead. “I thought, I’ll have one that looks like me,” says Hartley, 35, smoothing her golden hair in the Los Angeles valley home she shares with her husband, Neil...
By Emily R. Klancher Merchant, Los Angeles Review of Books | 08.22.2024
IN THE Operation Varsity Blues scandal of 2019, 50 wealthy parents were charged with trying to get their children into elite universities through fraudulent means. The story dramatically demonstrated the lengths to which some parents will go to ensure their...
By Julia Brown, The Conversation | 08.16.2024
With their primary goal to advance scientific knowledge, most scientists are not trained or incentivized to think through the societal implications of the technologies they are developing. Even in genomic medicine, which is geared toward benefiting future patients, time and...